Oral etopside and cyclophosphamide combination in patients with hormone-refractory prostate carcinoma
- VernacularTitle:足叶乙甙联合环磷酰胺治疗雄激素抵抗性前列腺癌
- Author:
Weiqing QIAN
;
Zhongquan SUN
;
Jianda SONG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Hormone refractory;
Etoposide;
Cyclophosphamide
- From:
Chinese Journal of Urology
2001;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of oral etopside (VP16) and oral cyclophosphamide (CPM) combination in the treatment of hormone-refractory prostate cancer (HRPC). Methods Between June 2000 and July 2003,9 patients with HRPC were treated with oral etopside (50 mg/d) and oral cyclophosphamide (100 mg/d) for 21 days with every 28 days as a cycle.Inclusion criteria were previous complete androgen blockade,anti-androgen (flutamide) withdrawal evaluation,and clinical or biochemical disease progression.The therapy was continued until there was evidence of disease progression or the patients could not tolerate the adverse effects of the medications. Results All the 9 patients had a mean follow-up of 7.5 months.PSA levels decreased by at least 50%,from pre-treatment of (90.5?43.6)ng/ml to post-treatment of (24.8?22.2)ng/ml,in 4 patients. The mean duration of response was 6.8 months (range,2-15 months).An objective response was obtained in 2 patients (1 of CR and 1 of PR).Toxic and adverse effects were minimal. Conclusions The combination of oral VP16 and CPM may be an efficacious and well-tolerated regimen in patients with HRPC.
